Drug Trial Radar · NCT07251023
Efficacy and Safety of DMB-I (INN: Latrepirdine) in Patients With Alzheimer Type Dementia
Last checked: Nov 19, 2026Latest source record: Dec 10, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
450
Planned (sponsor's estimate)
Start
Nov 20, 2025
Primary completion
May 2027
Study completion May 2027
Sponsor
- Lead sponsor
- Bigespas LTDIndustry
- Sponsor type
- Industry
- First posted
- Nov 26, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 60 years, up to 90 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical study is to learn if the study drug DMB-I (INN: Latrepirdine) works to treat Alzheimer type dementia in adults. It will also learn about the safety of DMB-I (INN: Latrepirdine). The main questions it aims to answer are: * Does DMB-I improve cognitive functions in patients with dementia associated with Alzheimer's disease, and how sigificant the improvement is? * What medical problems do participants have when taking DMB-I? Researchers will compare DMB-I to a placebo (a look-alike substance that contains no drug) to see if the study drug works to treat Alzheimer type dementia. * Is DMB-I effective and safe when taken long-term? Participants will: Take the study drug or a placebo (with or without Akatinol Memantine®) every day for 26 weeks at Stage 1 of the study, and take the study drug (with or without Akatinol Memantine®) every day for 26 weeks at Stage 2 of the study. Visit the clinic 13 times for checkups and tests Keep a diary of their symptoms
Conditions
- Alzheimer Type Dementia
Interventions
DMB-I (INN: Latrepirdine)Drug
Active agent: Dimethylmethylpyridinylethyltetrahydrocarboline. Investigational drug in the study
Memantine Hydrochloride 20 MGDrug
Memantine is used to treat moderate to severe Alzheimer's disease. Active comparator drug in the study
PlaceboDrug
Placebo comparator (dummy) in the study.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Assessment of the change in ADAS-Cog Scale overall score at Week 26 compared to baseline (Week 0) in patients receiving DMB-I (Group 1) Vs. patients receiving placebo (Group 2)Time frame: Baseline (Week 0) Vs. Week 26
Locations
12 sites in 1 country. Site status is shown where the registry gives one.
State autonomous healthcare institution "Transregional Clinical Diagnostic Center"
Kazan', Russia · Recruiting
Moscow State budgetary healthcare institution "City Clinical Hospital named after V.M. Buyanov of the Moscow Healthcare Department"
Moscow, Russia · Recruiting
Federal State Budgetary Institution "Federal Center for Brain and Neurotechnology" of the Federal Medical and Biological Agency
Moscow, Russia · Recruiting
Federal State Autonomous Educational Institution of Higher Education I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University)
Moscow, Russia · Recruiting
Nizhny Novgorod region State budgetary healthcare institution " Nizhny Novgorod Clinical Psychiatric Hospital No. 1"
Nizhny Novgorod, Russia · Recruiting
State budgetary healthcare institution "Leningrad Regional Mental Health Center"
Roshchino, Russia · Recruiting
"Medical Center Nova Vita" LLC
Rostov-on-Don, Russia · Recruiting
Saint Petersburg State budgetary healthcare institution "Psychiatric Hospital No. 1 named after P.P. Kashchenko"
Saint Petersburg, Russia · Recruiting
"Medical services" LLC
Saint Petersburg, Russia · Recruiting
Saint Petersburg State budgetary healthcare institution "Psychoneurologic dispensary № 5"
Saint Petersburg, Russia · Recruiting
"Sphera Med" LLC
Saint Petersburg, Russia · Recruiting
Saint Petersburg State budgetary healthcare institution "City Hospital No. 40 of Kurortniy district"
Saint Petersburg, Russia · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.